PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

oleh: Kim Linton, Jeanette Doorduijn, Dima El-Sharkawi, Rogier Mous, Francesco Forconi, David Lewis, Mary Gleeson, John Riches, Pam Mckay, Wendy Stevens, Sarah G Injac, Graham P Collins